Literature DB >> 11012620

Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa.

K Yanagihara1, K Tomono, M Kuroki, Y Kaneko, T Sawai, H Ohno, Y Miyazaki, Y Higashiyama, S Maesaki, J Kadota, S Kohno.   

Abstract

We investigated the role of inflammatory cytokines in a mouse model of chronic Pseudomonas aeruginosa infection mimicking diffuse panbronchiolitis (DPB), and determined the effects of clarithromycin therapy on the production of these cytokines. The concentrations of IL-1beta, IL-2, IL-4, IL-5, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) were measured serially in the lungs of mice with experimentally induced chronic respiratory P. aeruginosa infection until 60 days after inoculation. The concentrations of these cytokines during the course of the disease were significantly higher than baseline (before inoculation, P<0.01 for all cytokines). Clarithromycin significantly inhibited the production of IL-1beta and TNF-alpha in the lung (P<0.01). The same treatment also reduced the levels of other cytokines, albeit insignificantly. Treatment with anti-TNF-alpha antibody significantly reduced the number of pulmonary lymphocytes and concentration of IL-1beta in the lung (P<0.01), but did not change the number of viable bacteria. Our findings resemble those detected in bronchoalveolar lavage fluid of patients with DPB and indicate that inflammatory cytokines play an important role in chronic P. aeruginosa lung infection. Our results also show that macrolides modulated the production of these cytokines, ultimately reducing lymphocyte accumulation in the lung. Our data suggest that anti-TNF-alpha antibody might be a useful new strategy for the treatment of chronic respiratory P. aeruginosa infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012620      PMCID: PMC1905753          DOI: 10.1046/j.1365-2249.2000.01343.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Purification and characterization of intraparenchymal lung lymphocytes.

Authors:  E Abraham; A A Freitas; A A Coutinho
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

Review 2.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

3.  [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis].

Authors:  S Kudoh; T Uetake; K Hagiwara; M Hirayama; L H Hus; H Kimura; Y Sugiyama
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1987-06

4.  Diffuse panbronchiolitis. A disease of the transitional zone of the lung.

Authors:  H Homma; A Yamanaka; S Tanimoto; M Tamura; Y Chijimatsu; S Kira; T Izumi
Journal:  Chest       Date:  1983-01       Impact factor: 9.410

5.  Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response.

Authors:  C Moser; H P Hougen; Z Song; J Rygaard; A Kharazmi; N Høiby
Journal:  APMIS       Date:  1999-12       Impact factor: 3.205

6.  Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis.

Authors:  P F Piguet; M A Collart; G E Grau; A P Sappino; P Vassalli
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

7.  Microbial pathogenesis in cystic fibrosis: pulmonary clearance of mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge.

Authors:  H Yu; M Hanes; C E Chrisp; J C Boucher; V Deretic
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

8.  Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis.

Authors:  A Sato; K Chida; M Iwata; H Hayakawa
Journal:  Am Rev Respir Dis       Date:  1992-08

9.  A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis.

Authors:  J Kadota; O Sakito; S Kohno; H Sawa; H Mukae; H Oda; K Kawakami; K Fukushima; K Hiratani; K Hara
Journal:  Am Rev Respir Dis       Date:  1993-01

10.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors:  Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  8 in total

1.  Clarithromycin in the Treatment of Legionella pneumophila Pneumonia Associated with Multiorgan Failure in a Previously Healthy Patient.

Authors:  L Gallelli; V Gioffrè; G Vero; A Gallelli; F Roccia; S Naty; G Pelaia; A Capano; A Loiacono; G De Sarro; R Maselli
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

2.  Acute infection with influenza virus enhances susceptibility to fatal pneumonia following Streptococcus pneumoniae infection in mice with chronic pulmonary colonization with Pseudomonas aeruginosa.

Authors:  M Seki; Y Higashiyama; K Tomono; K Yanagihara; H Ohno; Y Kaneko; K Izumikawa; Y Miyazaki; Y Hirakata; Y Mizuta; T Tashiro; S Kohno
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

3.  Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice.

Authors:  Wan C Tsai; Marc B Hershenson; Ying Zhou; Umadevi Sajjan
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

4.  Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model.

Authors:  Towako Nagata; Hiroshi Mukae; Junichi Kadota; Tomayoshi Hayashi; Takeshi Fujii; Misuzu Kuroki; Ryo Shirai; Katsunori Yanagihara; Kazunori Tomono; Takehiko Koji; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

5.  Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.

Authors:  Evangelos J Giamarellos-Bourboulis; Theodoros Adamis; George Laoutaris; Lambros Sabracos; Vassilios Koussoulas; Maria Mouktaroudi; Despina Perrea; Panayotis E Karayannacos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

6.  C-Reactive Protein-Based Strategy to Reduce Antibiotic Dosing for the Treatment of Pneumococcal Infection.

Authors:  Donald N Ngwa; Sanjay K Singh; Alok Agrawal
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 8.786

7.  A novel virulence strategy for Pseudomonas aeruginosa mediated by an autotransporter with arginine-specific aminopeptidase activity.

Authors:  Jeni C A Luckett; Owen Darch; Chase Watters; Manal Abuoun; Victoria Wright; Esteban Paredes-Osses; Jenny Ward; Hana Goto; Stephan Heeb; Stéphanie Pommier; Kendra P Rumbaugh; Miguel Cámara; Kim R Hardie
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

8.  Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids.

Authors:  B M Jones; E S K Ma; J S M Peiris; P C Wong; J C M Ho; B Lam; K N Lai; K W T Tsang
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.